Post-paracentesis circulatory derangements are related to monocyte activation

Liver International

Volumn 34, Issue 7, 2014, Pages 1001-1007

  Carl, Daniel E ^a   Ghosh, Siddharta ^a   Cheng, Jianfeng ^b   Gehr, Todd W B ^a   Stravitz, R Todd ^a   Sanyal, Arun ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b Carolina Medical Center   (United States)

Author keywords

24 h ambulatory blood pressure monitoring; Cirrhosis; Inflammation; Paracentesis

Indexed keywords

CYTOKINE; RENIN; SERUM ALBUMIN;

ADVERSE EFFECTS; ASCITES; BLOOD; BLOOD PRESSURE; COMPLICATION; FEMALE; HEMODYNAMICS; HUMAN; KIDNEY; LIVER CIRRHOSIS; MALE; METABOLISM; MIDDLE AGED; MONOCYTE; PARACENTESIS; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PROSPECTIVE STUDY; SHOCK; UNITED STATES; VASODILATATION;

ASCITES; BLOOD PRESSURE; CYTOKINES; FEMALE; HEMODYNAMICS; HUMANS; KIDNEY; LIVER CIRRHOSIS; MALE; MIDDLE AGED; MONOCYTES; PARACENTESIS; PROSPECTIVE STUDIES; RENIN; SERUM ALBUMIN; SHOCK; VASODILATION; VIRGINIA;

EID: 84904463512     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12450     Document Type: Article

References (39)

1. Gines P, Arroyo V, Quintero E, et al. Comparison of paracentesis and diuretics in the treatment of cirrhotics with tense ascites. Results of a randomized study. Gastroenterology 1987; 93: 234-41.
2. Pinto PC, Amerian J, Reynolds TB. Large-volume paracentesis in nonedematous patients with tense ascites: its effect on intravascular volume. Hepatology 1988; 8: 207-10.
3. Salerno F, Badalamenti S, Incerti P, et al. Repeated paracentesis and i.v. albumin infusion to treat 'tense' ascites in cirrhotic patients. A safe alternative therapy. J Hepatol 1987; 5: 102-8.
4. Salerno F, Borroni G, Moser P, et al. Survival and prognostic factors of cirrhotic patients with ascites: a study of 134 outpatients. Am J Gastroenterol 1993; 88: 514-9.
5. Luca A, Feu F, Garcia-Pagan JC, et al. Favorable effects of total paracentesis on splanchnic hemodynamics in cirrhotic patients with tense ascites. Hepatology 1994; 20: 30-3.
6. Simon DM, McCain JR, Bonkovsky HL, et al. Effects of therapeutic paracentesis on systemic and hepatic hemodynamics and on renal and hormonal function. Hepatology 1987; 7: 423-9.
7. Wang SS, Lu CW, Chao Y, et al. Total paracentesis in non-alcoholic cirrhotics with massive ascites: mid-term effects on systemic and hepatic haemodynamics and renal function. J Gastroenterol Hepatol 1994; 9: 592-6.
8. Pozzi M, Osculati G, Boari G, et al. Time course of circulatory and humoral effects of rapid total paracentesis in cirrhotic patients with tense, refractory ascites. Gastroenterology 1994; 106: 709-19.
9. Ruiz-del-Arbol L, Monescillo A, Jimenez W, et al. Paracentesis-induced circulatory dysfunction: mechanism and effect on hepatic hemodynamics in cirrhosis. Gastroenterology 1997; 113: 579-86.
10. Sola-Vera J, Such J. Understanding the mechanisms of paracentesis-induced crculatory dysfunction. Eur J Gastroenterol Hepatol 2004; 16: 295-8.
11. Sola-Vera J, Minana J, Ricart E, et al. Randomized trial comparing albumin and saline in the prevention of paracentesis-induced circulatory dysfunction in cirrhotic patients with ascites. Hepatology 2003; 37: 1147-53.
12. Moreau R, Asselah T, Condat B, et al. Comparison of the effect of terlipressin and albumin on arterial blood volume in patients with cirrhosis and tense ascites treated by paracentesis: a randomised pilot study. Gut 2002; 50: 90-4.
13. Gines A, Fernandez-Esparrach G, Monescillo A, et al. Randomized trial comparing albumin, dextran 70, and polygeline in cirrhotic patients with ascites treated by paracentesis. Gastroenterology 1996; 111: 1002-10.
14. Gines P, Tito L, Arroyo V, et al. Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis. Gastroenterology 1988; 94: 1493-502.
15. Salerno F, Badalamenti S, Lorenzano E, et al. Randomized comparative study of hemaccel vs. albumin infusion after total paracentesis in cirrhotic patients with refractory ascites. Hepatology 1991; 13: 707-13.
16. Schrier RW, Arroyo V, Bernardi M, et al. Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology 1988; 8: 1151-7.
17. Arroyo V, Gines P, Gerbes AL, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club. Hepatology 1996; 23: 164-76.
18. Gines P, Schrier RW. Renal failure in cirrhosis. N Engl J Med 2009; 361: 1279-90.
19. Moller S, Gulberg V, Henriksen JH, et al. Endothelin-1 and endothelin-3 in cirrhosis: relations to systemic and splanchnic haemodynamics. J Hepatol 1995; 23: 135-44.
20. Moore K, Wendon J, Frazer M, et al. Plasma endothelin immunoreactivity in liver disease and the hepatorenal syndrome. N Engl J Med 1992; 327: 1774-8.
21. Angus PW. Role of endothelin in systemic and portal resistance in cirrhosis. Gut 2006; 55: 1230-2.
22. Giron-Gonzalez JA, Martinez-Sierra C, Rodriguez-Ramos C, et al. Implication of inflammation-related cytokines in the natural history of liver cirrhosis. Liver Int 2004; 24: 437-45.
23. Tazi KA, Quioc JJ, Saada V, et al. Upregulation of TNF-alpha production signaling pathways in monocytes from patients with advanced cirrhosis: possible role of Akt and IRAK-M. J Hepatol 2006; 45: 280-9.
24. Sundaram V, Shaikh OS. Hepatic encephalopathy: pathophysiology and emerging therapies. Med Clin North Am 2009; 93: 819-36.
25. Kappus MR, Bajaj JS. Covert hepatic encephalopathy: not as minimal as you might think. Clin Gastroenterol Hepatol 2012; 10: 1208-19.
26. Wiest R, Das S, Cadelina G, et al. Bacterial translocation in cirrhotic rats stimulates eNOS-derived NO production and impairs mesenteric vascular contractility. J Clin Invest 1999; 104: 1223-33.
27. Romero-Sanchez M, Gonzalez-Serna A, Pacheco YM, et al. Different biological significance of sCD14 and LPS in HIV-infection: importance of the immunovirology stage and association with HIV-disease progression markers. J Infect 2012; 65: 431-8.
28. Stehle JR Jr, Leng X, Kitzman DW, et al. Lipopolysaccharide-binding protein, a surrogate marker of microbial translocation, is associated with physical function in healthy older adults. J Gerontol A Biol Sci Med Sci 2012; 67: 1212-8.
29. Balagopal A, Philp FH, Astemborski J, et al. Human immunodeficiency virus-related microbial translocation and progression of hepatitis C. Gastroenterology 2008; 135: 226-33.
30. Panos MZ, Moore K, Vlavianos P, et al. Single, total paracentesis for tense ascites: sequential hemodynamic changes and right atrial size. Hepatology 1990; 11: 662-7.
31. Egashira K. Molecular mechanisms mediating inflammation in vascular disease: special reference to monocyte chemoattractant protein-1. Hypertension 2003; 41: 834-41.
32. Munshi R, Johnson A, Siew ED, et al. MCP-1 gene activation marks acute kidney injury. J Am Soc Nephrol 2011; 22: 165-75.
33. Murali NS, Ackerman AW, Croatt AJ, et al. Renal upregulation of HO-1 reduces albumin-driven MCP-1 production: implications for chronic kidney disease. Am J Physiol Renal Physiol 2007; 292: F837-44.
34. Rice JC, Spence JS, Yetman DL, et al. Monocyte chemoattractant protein-1 expression correlates with monocyte infiltration in the post-ischemic kidney. Ren Fail 2002; 24: 703-23.
35. Fagundes C, Gines P. Hepatorenal syndrome: a severe, but treatable, cause of kidney failure in cirrhosis. Am J Kidney Dis 2012; 59: 874-85.
36. Albillos A, de la Hera A, Gonzalez M, et al. Increased lipopolysaccharide binding protein in cirrhotic patients with marked immune and hemodynamic derangement. Hepatology 2003; 37: 208-17.
37. Rasaratnam B, Kaye D, Jennings G, et al. The effect of selective intestinal decontamination on the hyperdynamic circulatory state in cirrhosis. A randomized trial. Ann Intern Med 2003; 139: 186-93.
38. Schumann RR, Latz E. Lipopolysaccharide-binding protein. Chem Immunol 2000; 74: 42-60.
39. Ziegler-Heitbrock HW, Ulevitch RJ. CD14: cell surface receptor and differentiation marker. Immunol Today 1993; 14: 121-5.